Navigation Links
Multiple Programs from Merrimack Pharmaceuticals' Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:11/11/2011

CAMBRIDGE, Mass., Nov. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics taking place November 12-16, 2011, in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-398MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan.  The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer.  PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.  Title:  Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan

Poster Session: Topoisomerase Inhibitors

Number: C207

Date/Time: Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-121 MM-121 is a monoclonal antibody designed to block signaling through the ErbB3 (HER3) receptor. MM-121, in partnership with Sanofi, is in clinical development in patients with breast, lung and ovarian cancer.Title:  Targeting ErbB3 (HER3) and EGFR in Lung Cancer Patients: A Phase I Trial of MM-121 in Combination with Erlotinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Poster Session: Clinical Trials 3

Number: C27

Date/Time: Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-111MM-111 is a novel bispecific antibody against ErbB3 (HER3), using an ErbB2 (HER2) targeting arm to enhance avidity and inhibition.  Title:  Optimizat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Application Enables Collaboration by Connecting SciVerse ... , Elsevier , a world-leading provider of scientific, technical ... of an expert identification and discovery application that connects ... and research synthesis, with the DIRECT2Experts online ...
... 14, 2012  Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") ... on February 8, 2012, with Organovo, Inc. (the ... three-dimensional bioprinting technology for research and medical applications.  ... placement consisting of approximately 6.5 million units of ...
Cached Medicine Technology:Elsevier Introduces Expert Discovery Application for SciVerse Hub 2Elsevier Introduces Expert Discovery Application for SciVerse Hub 3Elsevier Introduces Expert Discovery Application for SciVerse Hub 4Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:4/18/2014)... A new medical-testing device is being prepped to ... could improve diagnosis of certain diseases in remote ... a series of investigations aboard the International Space ... uses the space-tested concept of capillary flow to ... , David Kelso, Ph.D., a researcher at Northwestern ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , MONDAY, March 14 (HealthDay News) -- Women may ... a diet rich in two types of B vitamins, a ... and riboflavin (B2) in their food significantly reduced their risk ... fortified cereals, whole grains, beans and nuts, and researchers said ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, March ... that is, a pediatrician or nurse they see regularly who offers ... dental needs met, new research finds. Yet it,s the sickest ... and require the most care -- who are less likely to ...
... the globe are making headway in fighting communicable diseases ... research from the Frederick S. Pardee Center for International ... School of International Studies. The center ... volumes that focus on human progress in which researchers ...
... human studies of an oral drug regimen to prevent HIV ... in HIV incidence, but a number of issues require additional ... a large scale, according to an article in AIDS ... Mary Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... Research and Education recently received a five year, $3.7 ... and Agriculture to fund a project aimed at preventing ... to teach mothers simple yet authoritative strategies to promote ... The grant was awarded to Jenifer Orlet Fisher, associate ...
... ,Scientists at the National Institute of Allergy and Infectious ... have shown how the O157:H7 strain of Escherichia ... host immune response. The bacterium secretes a protein called ... alter specific immune responses. This process not only helps ...
Cached Medicine News:Health News:Diets Rich in Vitamin B May Help Prevent PMS, Study Finds 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:DU researchers find that headway being made fighting communicable diseases globally 2Health News:DU researchers find that headway being made fighting communicable diseases globally 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Temple receives $3.7 million to study parenting styles' effect on childhood obesity 2
Baby Weitlaner retractor, blunt, 4"....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
15" overall length, 5" handle....
15" overall length, 9" handle....
Medicine Products: